Stock of the day: ResMed
ResMed secures US tariff exemptions and reports 8% revenue growth to $1.3 billion while doubling California manufacturing capacity.
(AI video summary)
This video was created on 24 April for IG audiences by ausbiz.
ASX code: RMD
ResMed's tariff exemption boosts outlook
ResMed has received exemption from United States (US) trade tariffs for its exports from manufacturing facilities in Australia and Singapore. Chief Executive Officer (CEO) Mick Farrell acknowledges uncertainties under the current US administration, prompting the company to double its California manufacturing footprint to manage geopolitical risks.
Strong quarterly performance
- Quarterly revenue increased 8% to $1.3 billion, driven by demand for sleep devices and masks, plus growth in residential care software
- Gross margin improved by 140 basis points (bps) to 59.3%
- Operating income rose 14%, posting $579 million in operating cash flow,
- Diluted earnings per share (EPS) of $2.48, paying $78 million in dividends
ResMed shares have risen in morning trading following this report.
Investment perspective
Analysts view ResMed as a quality growth company with strong management, demonstrated by 9% constant currency revenue growth and expanding margins.
Some investors maintain current positions due to recent share price appreciation, while others see opportunities to increase holdings. The company's adaptability and innovation pipeline make it an attractive long-term investment.
Analysts consider potential tariff impacts as temporary, likely to be overshadowed by broader US fiscal challenges.
News and trade ideas
Gold
-
Which ASX sectors and commodities show resilience as trade tensions reshape regional markets?
Australia's energy, mining and resource sectors face contrasting outlooks as commodity prices fluctuate amid evolving Asian trade partnerships and ren...Forex -
-
-
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Explore the markets with our free course
Learn how shares work – and discover the wide range of markets you can trade on – with IG Academy's free ’introducing the financial markets’ course.
Put learning into action
Try out what you’ve learned in this shares strategy article risk-free in your demo account.
Ready to trade shares?
Put the lessons in this article to use in a live account – upgrading is quick and easy.
- Trade over 16,000 popular global stocks
- Protect your capital with risk management tools
- React to breaking news with out-of-hours trading on 70 key US stocks
Inspired to trade?
Put your new knowledge into practice. Log in to your account now.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
